Experimental research on TECA-I bioartificial liver support system to treat canines with acute liver failure

Xiao-Ping Chen¹, Yi-Long Xue¹, Xin-Jian Li¹, Zuo-Yun Zhang¹, Yan-Ling Li² and Zhi-Qiang Huang²

¹Institute of Basic Medical Sciences, 2Department of Hepatobiliary Surgery, PLA General Hospital, Beijing 100853, China
Correspondence to: Dr. Yi-Long Xue, Institute of Basic Medical Sciences, PLA General Hospital, Beijing 100853, China. xueyl@plagh.com.cn
Received 2001-05-12 Accepted 2001-06-20

Abstract
AIM To evaluate the efficacy and safety of the TECA-I bioartificial liver support system (BALSS) in treating canines with acute liver failure (ALF).

METHODS Ten canines with ALF induced by 80% liver resection received BALSS treatment (BALSS group). Blood was perfused through a hollow fiber tube containing 1×10¹⁰ porcine hepatocytes. Four canines with ALF were treated with BALSS without porcine hepatocytes (control group), and five canines with ALF received drug treatment (drug group). Each treatment lasted 6 hours.

RESULTS BALSS treatment yielded beneficial effects for partial liver resection-induced ALF canines with survival and decreased plasma ammonia, ALT, AST and BIL. There was an obvious decrease in PT level and increase in PA level, and there were no changes in the count of lymphocytes, immunoglobulins (IgA, IgG and IgM) and complement (C3 and C4) levels after BALSS treatment. In contrast, for the canines with ALF in non-hepatocyte BALSS group (control group) and drug group, there were no significant changes in ammonia, ALT, AST, BIL, PT and PA levels. ALF canines in BALSS group, control group and drug group lived respectively an average time of 108.0 h±12.0 h, 24.0 h ±6.0 h and 20.4 h ±6.4 h, and three canines with ALF survived in BALSS group.

CONCLUSION TECA-I BALSS is efficacious and safe for ALF canines induced by parcial liver resection.

Subject headings liver, artificial; liver failure, acute/surgery; liver failure, acute/physiopathology; liver failure, acute/immunology

Chen XP, XueYL, Li XJ, Zhang ZY, Li YL, Huang ZQ. Experimental research on TECA-I bioartificial liver support system to treat canines with acute liver failure. World J Gastroenterol, 2001;7 (5):706-709

INTRODUCTION The incidence of acute liver failure (ALF) is high, and the survival rate of ALF patients is only 10%-15%[1,2]. The current comprehensive treatment for ALF is not satisfactory. Orthotopic liver transplantation (OLT) is an effective therapy for patients with ALF. However, because of the shortage of donor organs, many patients died before they could receive OLT. The recently developed bioartificial liver support system can temporarly replace the complex functions of liver such as synthesis, detoxication and “bridge” the patients with ALF to liver transplantation. To what extent can TECA-I BALSS replace normal liver functions In order to answer the question, we have introduced the basic techniques of a hollow fiber bioartificial liver system, used Chinese experimental miniature swines as the donor of xenogeneic hepatocytes, improved the culturing conditions of porcine hepatocytes in the BALSS, and identified the efficacy and safety of TECA-I BALSS in treating drug-induced ALF canines[3,4]. In the present study, we developed a partial liver resection-induced ALF canine model to assess the efficacy and feasibility of the TECA-I BALSS in treating ALF canines.

MATERIALS AND METHODS
Animal
Nineteen healthy adult hybrid canines weighing 18 kg-22 kg were obtained from the Experimental Center of General Hospital of PLA, and fourteen adult Chinese experimental miniature swines weighing 8 kg-10 kg from the Breed Center of Chinese Agricultural University.

Reagents
All chemicals were provided by Hong Kong TECA Ltd Co. and Sigma Chemical Co.

Development of a canine model of ALF
The canines received eighty percent liver resection. Left lateral, left anterior, right lateral and caudate lobe were removed.

Isolation and culturing of porcine hepatocytes
Hepatocytes were isolated from Chinese experimental miniature swines by collagen ase digestion. Viability of the cells was assayed by trypan blue exclusion and AO/PI fluorescence staining.

BALSS treatment
Freshly isolated hepatocytes were cultured in the TECA-I BALSS provided by Hong Kong Ltd Co. The porcine hepatocytes circulated through the exterior space of capillary hollow fiber in the BALSS. Blood from femoral artery and vein on one side of the ALF canine circulated through the inner space of capillary hollow fiber and the substances exchanged through the membrane of hollow fibers between porcine hepatocytes and ALF blood.

Experimental groups
Nineteen ALF canines were randomly divided into three groups: (1) BALSS group (n = 10): perfused with hollow fiber...
tube of BALSS containing $1 \times 10^{10}$ porcine hepatocytes. ② non-hepatocyte BALSS group (control group, $n = 4$): perfused with hollow fiber tube without porcine hepatocytes. ③ drug group ($n = 5$): intravenous injection with arginine, sodium glutamate and branch amino acid. Each treatment lasted six hours.

**Biochemical assays**
The plasma levels of ammonia, ALT, AST, bilirubin, PT and PA were measured before and 2, 4, 6 hours, 1, 3, 5, 7, 14 and 30 days after treatment.

**Immunological assays**
The count of lymphocytes, immunoglobulins (IgA, IgG, IgM) and complement (C3, C4) levels were measured before and 7, 14 and 30 days after BALSS treatment.

**Morphological observation**
The volume of the remnant liver was observed, and the remnant liver, kidneys, heart and lungs were taken out when the canines died or survived for 30 days for paraffin section, and HE stained and examined under light microscope.

**Statistical analyses**
The values of blood biochemical and immunological parameters were expressed as means±SD. Data of pre- and post-treatment among the three groups were compared using the Chi square test. The differences were considered significant at $P < 0.05$.

**RESULTS**

**Development of ALF canine models induced by eighty percent liver resection (Figures 1-6)**
The canines demonstrated a significant increase in plasma ammonia, ALT, AST, bilirubin and PT levels, and decrease in PA level 24 hours after operation: ammonia ($64.52 \pm 10.07 \text{ µmol/L}$-$128.33 \pm 17.32 \text{ µmol/L}$, Figure 1), ALT ($14.33 \pm 5.12 \text{ IU/L}$-$277.04 \pm 53.35 \text{ IU/L}$, Figure 2), AST ($16.56 \pm 8.91 \text{ IU/L}$-$236.06 \pm 75.68 \text{ IU/L}$, Figure 3), BIL ($5.07 \pm 1.56 \text{ mmol/L}$-$21.20 \pm 3.22 \text{ mmol/L}$, Figure 4), PT ($9.68 \pm 0.76 \text{ s}$-$19.91 \pm 1.87 \text{ s}$, Figure 5) and PA ($79.16 \pm 4.31\%$-$54.66 \pm 4.84\%$, Figure 6). ICG excretion rate of post-operation was lower than that of pre-operation respectively at 5, 10 and 15 minutes (15%, 23% and 30% vs 20%, 55% and 76%).

**Porcine hepatocytes**
Using the modified enzymatic digestive method, each liver yielded approximately $1-3 \times 10^{10}$ hepatocytes. Viability of the final suspensions averaged 75%-90% by typan blue exclusion and AO/PI fluorescence staining.

**Liver and clotting function recovery of ALF canines after treatment with BALSS**
BALSS treatment yielded beneficial effects with decreased plasma ammonia, bilirubin at 2 hours of the treatment, and then returned to normal from 4-6 hours of the treatment. There was an obvious decrease in PT, ALT and AST level and increase in PA level at 7 days after BALSS treatment. In contrast, there were no changes in ammonia, ALT, AST, bilirubin, PT and PA levels for the ALF canines in the control group and drug group. Among seven of ten canines in BALSS group which received one BALSS treatment, only one survived, and six lived an average time of 108.0 h±12.0 h (96 h-120 h). Three often canines received two BALSS treatments, two canines survived, and one died of lung infarction. There was no evidence that BALSS treatment had adverse effects on the morphology of kidneys, lungs and heart. In contrast, four ALF canines in the control group lived an average time of 24.0 h±6.0 h (18 h-50 h). Five ALF canines in the drug group lived an average time of 20.4 h±6.4 h (12 h-28 h).

**Figure 1** Effects of the BALSS on ammonia of subtotal hepatectomy induced ALF canines.

**Figure 2** Effects of the BALSS on GPT of subtotal hepatectomy induced ALF canines.

**Figure 3** Effects of the BALSS on GOT of subtotal hepatectomy induced ALF canines.

**Figure 4** Effects of the BALSS on bilirubin of subtotal hepatectomy induced ALF canines.
There are possible dangers of the tumor cells of hepatocytes in our experiment. Using modified enzymatic pure strain Chinese experimental miniature swine as the source hinders the application of BALSS, we therefore selected the tumor cell lines\(^[5,6]\), human embryo\(^[7]\) and porcine main biological material is hepatocytes which include human BALSS is made of biological and synthetic materials. The substance with ALF blood so that it can temporarily replace BALSS, xenogeneic hepatocytes were used to exchange the has been made in the experimental and clinical research. In currently developed bioartificial liver support system normal liver function. Although in the development of a bioartificial liver, the use of hepatocytes from xenogeneic origin is the most promising alternative for human hepatocytes due to the shortage of human donor material, potential immunological problems may arise. The central unit of TECA-I BALSS is the so-called bioreactor (hollow fiber tube) which is divided into two sets of compartment (hollow fiber tube) and was metabolized by porcine hepatocytes through urea cycle enzymes and glutamine synthetase. Significant decreases in plasma bilirubin levels after BALSS treatment were observed and demonstrated that porcine hepatocytes cultured in BALSS could accelerate metabolism of bilirubin in ALF blood. It was reported that hyperbilirubinemia in animals had been corrected by microencapsulated hepatocyte transplantation. Results of a phase I clinical trial of BALSS treatment showed that more than two BALSS treatments could clear the toxins in ALF blood completely and provide sufficient metabolic, liver functional support\(^[9,10]\). Our experiment indicated that the survival rate of ALF canines that received two BALSS treatments was higher than that of ALF canines that received only one BALSS treatment. Certainly the ultimate goal of a liver support treatment is to treat patients early enough and repeatedly to allow them to regenerate their livers and recover normal liver function. The central unit of TECA-I BALSS is the so-called bioreactor (hollow fiber tube) which is divided into two sets of compartment by semipermeable membrane: extracapillary and intracapillary compartment. The semipermeable membrane is set such that those substances which are metabolized, detoxified, or synthesized can readily cross the membrane. However, blood cells and hepatocytes should not cross the reactor membrane. In our experiment, in the 3 survived canines, there was neither change in the count of lymphocytes, immune proteins (IgA, IgG, IgM) and supplementary (C3, C4) levels and nor pathological change in kidneys, remnant liver, lungs and heart. **DISCUSSION**

Acute liver failure is a kind of severe disease, and no effective clinical therapy is available currently. Since the liver has many complex physiological functions, such as synthesis, detoxication and biotransformation. The current non-bioartificial liver, for example, activated charcoal hemoperfusion and plasma exchange can not replace the liver function completely. It only can clear some middle and small molecule weight substance in circulation. Fortunately, encouraging success of currently developed bioartificial liver support system has been made in the experimental and clinical research. In BALSS, xenogeneic hepatocytes were used to exchange the substance with ALF blood so that it can temporarily replace the complex liver functions.

BALSS is made of biological and synthetic materials. The main biological material is hepatocytes which include human liver tumor cell lines\(^[5,6]\), human embryo\(^[7]\) and porcine hepatocytes\(^[9]\). There are possible dangers of the tumor cells to receptors and the scarce of the embryonic liver cells which hinders the application of BALSS, we therefore selected the pure strain Chinese experimental miniature swine as the source of hepatocytes in our experiment. Using modified enzymatic digesting and culturing method, we acquired a large quantity of porcine hepatocytes to meet the needs of BALSS. Porcine hepatocytes 1-3×10\(^9\) could be acquired from one swine liver, and the viability of hepatocytes reached 75%–90%. Hollow fiber tube is the main synthetic material in which hepatocytes are cultured and exchange substance with ALF blood through semipermeable membrane. A surgical model of acute liver failure is preferred to a toxic model, because it is more reproducible and induces only liver damage. In our study, we developed a subtotal hepatectomy induced ALF canine model. Twenty-four hours after operation, the blood hepatic biochemical parameters had obvious changes. The ALF canines died within 36–52 hours without treatment. The ALF canine model had a good reproductivity and could suit the studies of BALSS.

One of the most striking observations from the present work is that the ammonia level of the ALF canines in BALSS group were lowered dramatically at 2 hours of the treatment, and then returned to normal from 4-6 hours of the treatment. In contrast, there were no changes in the ammonial level for the ALF canines in the control group and drug group. The result indicated that ammonia could move through the semipermeable membrane of hollow fiber tube and was metabolized by porcine hepatocytes through urea cycle enzymes and glutamine synthetase. Significant decreases in plasma bilirubin levels after BALSS treatment were observed and demonstrated that porcine hepatocytes cultured in BALSS could accelerate metabolism of bilirubin in ALF blood. It was reported that hyperbilirubinemia in animals had been corrected by microencapsulated hepatocyte transplantation. **Immunological changes of ALF canines after BALSS treatment**

There were no changes in count of lymphocytes, immunoglobulins (IgA, IgG, IgM) and complement (C3, C4) levels for 3 survived canines.

**Morphological changes of remnant liver, kidneys, lungs and heart of ALF canines after treatment with BALSS**

The volume of the remnant liver at 30 days after treatment became larger than that of ALF canines before treatment. BALSS treatment had no adverse effects on the morphology of kidneys, lungs and heart.
involved\textsuperscript{12}.

It is suggested that the TECA-I BALSS could temporarily replace the hepatic function of ALF canines effectively and safely, and it may provide a new approach for the treatment of ALF.

REFERENCES

1. Ascher NL, Lake JR, Emond JC, Roberts JP. Liver transplantation for fulminant hepatic failure. \textit{Arch Surg}, 1993;128:677-682
2. Pan BR, Yang SF, Ma LS. Acute liver failure: a progress report. \textit{China Natl J New Gastroenterol}, 1995;1:4-8
3. Xue YL, Zhao SF, Zhang ZY, Wang YF, Li XJ, Huang XQ, Luo Y, Zhang L, Huang YC, Liu CG. Effects of a hollow fiber bioartificial liver system to treat acute liver failure canines. \textit{Jiang Jiuxiu Xueyuan Xuexiao}, 1998;19:83-86
4. Xue YL, Zhao SF, Zhang ZY, Wang YF, Li XJ, Huang XQ, Luo Y, Huang YC, Liu CG. Effects of a bioartificial liver support system on acetaminophen-induced acute liver failure canines. \textit{World J Gastroenterol}, 1999;5:308-311
5. Gao Y, Xu XP, Hu HZ, Yang JZ. Cultivation of human liver cell lines with microcarriers acting as biological materials of bioartificial liver. \textit{World J Gastroenterol}, 1999;5:221-224
6. Sussman NL, Chong MG, Koussayer T. Reversal of fulminant hepatic failure using an extra corporeal liver assist device. \textit{Hepatology}, 1992;16:60-65
7. Wang YJ, Li MD, Wang YM, Chen GZ, Lu GD, Tan ZX. Effect of extracorporeal bioartificial liver support system on fulminant hepatic failure rabbits. \textit{World J Gastroenterol}, 2000;6:252-254
8. Lin C, Hou KY, Zhang WX, Lu JN, Zhou XS, Gong YD, Ding XL, Zhang XF, Zhao NM. Study on mechanism of treating acute hepatic failure with cryopreserved porcine hepatocyte xenotransplantation. \textit{China Natl J New Gastroenterol}, 1996;2:212-214
9. Rozga J, Podesta L, LePage E, Morsiani E, Moscioni A, Hoffman A, Sher L, Villamil F, Woolf G, McGrath M, Kong L, Rosen H, Lannan T, Vierling J, Makowka L, Demetriou AA. A bioartificial liver to treat severe acute liver failure. \textit{Ann Surg}, 1994;219:538-546
10. Watanabe FD, Mullon CJP, Hewitt WR, Arkadopoulos N, Kahaku E, Eguchi S, Khalili T, Arnaout W, Shackleton CR, Rozga J, Solomon B, Demetriou AA. Clinical experience with a bioartificial liver in the treatment of severe liver failure. \textit{Ann Surg}, 1997;225:484-494
11. Ribeiro J, Nordinger B, Ballet F. Intrasplenic hepatocellular transplantation corrects hepatic encephalopathy in porta-caval shunted rats. \textit{Hepatology}, 1992;15:12-18
12. Roger V, Balladur P, Honigier J, Baudrimont M, Delelo R, Robert A, Calmus Y, Capeau J, Nordlinger B. Internal bioartificial liver with xenogeneic hepatocytes prevents death from acute liver failure. \textit{Ann Surg}, 1998;228:1-7

Edited by Ma JY